logo
Share SHARE
FONT-SIZE Plus   Neg

AMAG Pharma Says Ferumoxytol Gets European Marketing Authorization To Treat IDA

AMAG Pharmaceuticals Inc. (AMAG) announced that the European Commission has granted marketing authorization for ferumoxytol, an intravenous or IV iron therapy to treat iron deficiency anemia or IDA in adult patients with chronic kidney disease or CKD.

The company said that the marketing authorization followed a positive opinion, issued on April 19, 2012, by the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency.

Ferumoxytol was approved for the same indication in the US under the brand name Feraheme in June 2009.

The company said that the marketing authorization is valid in the current European Union Member States as well as in Iceland and Norway, and is based on data obtained from an extensive clinical development program. Takeda Pharmaceutical Company Limited, AMAG's partner in Europe, plans to launch ferumoxytol in Europe under the brand name Rienso in 2012.

The company also said that the EU marketing authorization triggers a $15 million milestone payment to AMAG from Takeda; the first commercial sale of Riensoin Europe will trigger another $15 million milestone payment to AMAG. Additionally, AMAG is entitled to receive tiered, double-digit royalties on sales of Rienso in the licensed territories.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Ride-sharing company Uber Technologies Inc. is partnering with aircraft manufacturers to develop an on-demand network of vertical takeoff and landing vehicles. Uber plans to roll out flying cars with a pilot in the Dallas-Fort Worth area by 2020 and flights in Dubai at Expo2020, Chief Product Officer... Subway, the largest restaurant chain in the US by number of locations, closed more stores than it opened in 2016. This for the first time in its history that the company's store count dropped slightly after it closed more stores than it opened in 2016. The chain has always touted that it had more... Twitter Inc. reported narrower net loss in its first quarter and higher adjusted EBITDA margin as it remains focused on streamlining cost structure. Revenues declined on lower advertising and US revenues. However, adjusted earnings per share and revenues topped market estimates. In pre-market activity on the NYSE, Twitter shares were gaining 10.5 percent.
comments powered by Disqus
Follow RTT